Journal
EPILEPSY RESEARCH
Volume 85, Issue 1, Pages 123-127Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eplepsyres.2009.02.019
Keywords
Traumatic brain injury; Epilepsy; Rimonabant; CB1
Categories
Funding
- US National Institutes of Health [NS35915]
- UCI Medical Scientist Training Program
Ask authors/readers for more resources
Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have yielded no long-term antiepileptogenic effects. We report that a single, rapid post-traumatic application of the proconvulsant cannabinoid type-1 (CB1) receptor antagonist SR141716A (Rimonabant-Acomplia (R)) abolishes the long-term increase in seizure susceptibility caused by head injury in rats. These results indicate that, paradoxically, a seizure-enhancing drug may disrupt the epileptogenic process if applied within a short therapeutic time window. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available